Innovent to seek China approval of high-dose obesity shot after Phase 3 hitnews2025-11-20T11:30:31+00:00November 20th, 2025|Endpoints News|
PBMs, FTC clash in court over agency’s in-house insulin challengenews2025-11-19T20:45:14+00:00November 19th, 2025|Endpoints News|
New tuberculosis treatment shows potential in a Phase 2 studynews2025-11-19T19:05:40+00:00November 19th, 2025|Endpoints News|
Agios’ sickle cell trial falls short as drug doesn’t appear to help patient pain crisesnews2025-11-19T16:28:26+00:00November 19th, 2025|Endpoints News|
New prime editing approach could create one-size-fits-many therapiesnews2025-11-19T16:17:20+00:00November 19th, 2025|Endpoints News|
Protara trumpets small rare disease dataset in children for cell therapynews2025-11-19T15:57:02+00:00November 19th, 2025|Endpoints News|
Merck says once-daily HIV drug combo succeeds in another Phase 3news2025-11-19T14:51:35+00:00November 19th, 2025|Endpoints News|
New report suggests America must wean off China APIsnews2025-11-18T20:37:33+00:00November 18th, 2025|Endpoints News|
Roche’s oral SERD delays early breast cancer recurrence in late-stage trialnews2025-11-18T12:08:53+00:00November 18th, 2025|Endpoints News|
Lifordi gets new funding from Sanofi as it preps to test ADC in rheumatoid arthritisnews2025-11-18T12:00:59+00:00November 18th, 2025|Endpoints News|
